Call Now +233 20 386 3854

Tirzepatide Injection

Overview of Tirzepatide Injection

  • 2.5mg/0.5mL
  • 5mg/0.5mL
  • 7.5mg/0.5mL
  • 10mg/0.5mL
  • 12.5mg/0.5mL
  • 15mg/0.5mL


Tirzepatide has demonstrated its effectiveness in promoting weight loss among individuals who are overweight. Currently, phase 3 clinical trials are underway to investigate its potential for weight loss in adults who are overweight, obese, or experiencing weight-related health issues. The notable progress of Tirzepatide has led to its FDA Fast Track designation, expediting the application process for its approval in treating adults with obesity or those who are overweight and have weight-related health conditions.

During the SURMOUNT-1 clinical trial, it was observed that the average weight loss achieved with tirzepatide after 72 weeks was significant. The 5mg dose resulted in a 15% weight reduction, the 10mg dose led to a 19.5% weight reduction, and the 15mg dose demonstrated a remarkable 20.9% weight reduction.

It is important to note that Tirzepatide has been FDA-approved for its effectiveness in lowering blood sugar levels in individuals with type 2 diabetes. It is recommended to use Tirzepatide in conjunction with a proper diet and regular exercise regimen for optimal results.

By providing this information, we aim to ensure transparency and clarity regarding the potential benefits and approved uses of Tirzepatide.


On the basis of findings in rats and mice, may cause thyroid C-cell tumors, including MTC, in humans; human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, observed in patients treated with GLP-1 receptor agonists; after initiating, monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain, which sometimes radiates to the back and may or may not be accompanied by vomiting); if pancreatitis suspected, discontinue and do not restart if confirmed

Rapid improvement in glucose control associated with temporary worsening of diabetic retinopathy; tirzepatide has not been studied in patients with nonproliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema; monitor patients with a history of diabetic retinopathy

Gastrointestinal (GI) adverse reactions, sometimes severe, reported; has not been studied in patients with severe GI disease, including severe gastroparesis, and is not recommended in these patients

Acute gallbladder disease (eg, cholelithiasis, cholecystitis) reported in GLP-1 receptor agonist trials and postmarketing surveillance; if suspected, gallbladder studies and appropriate clinical follow-up are indicated

Kidney injury

  • Acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis in patients treated with GLP-1 receptor agonists, has been described
  • Most reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration
  • Events also reported in patients without known underlying renal disease
  • Monitor renal function when initiating or escalating doses in patients reporting severe adverse GI reactions


  • Serious hypersensitivity reactions reported with GLP-1 receptor agonists; caution in patients with history of angioedema or anaphylaxis with a GLP-1 receptor agonist
  • Unknown whether such patients will be predisposed to these reactions with tirzepatide
  • If hypersensitivity reactions occur, discontinue treatment, treat promptly, and monitor until signs and symptoms resolve

Drug interaction overview

  • Insulin secretagogues or insulin
    • May require dosage modification
    • Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin may increase risk of hypoglycemia
    • Consider lower dose of secretagogue or insulin to reduce risk of hypoglycemia
    • Inform patients using concomitant medications of risk of hypoglycemia and educate them on signs and symptoms of hypoglycemia
  • Oral drugs with narrow therapeutic index
    • Caution/dosage modification
    • Tirzepatide may delay gastric emptying, thereby potentially impacting oral absorption
    • Caution with drugs having a narrow therapeutic index (eg, warfarin)
    • Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or to add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each tirzepatide dose escalation

Refrigerate at 2-8ºC (36-46ºF)

If needed, each single-dose pen can be stored unrefrigerated at temperatures not to exceed 30ºC (86ºF) for up to 21 days

Do not freeze; do use if frozen

Protect from light